Suchergebnisse - "Wuerstlein, Rachel"

PubPharm (20)

1

Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

enthalten in: Cancer treatment reviews | 2023

von Harbeck, N. | Kates, R. | Schinköthe, T. | +15

2

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer : 5-Year Survival in the WSG-ADAPT-TP Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Harbeck, N. | Nitz, U. | Christgen, M. | +25

3

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer : The Neoadjuvant WSG-TP-II Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Gluz, O. | Nitz, U. | Christgen, M. | +17

4

PRECYCLE : multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

enthalten in: Trials | 2023

von Degenhardt, T. | Fasching, P. | Lüftner, D. | +20

5

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Graeser, M. | Gluz, O. | Biehl, C. | +24

6

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Müller, V. | Hein, A. | Hartkopf, A. | +26

7

Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting

enthalten in: International journal of molecular sciences | 2022

von Erber, R. | Angeloni, M. | Stöhr, R. | +23

8

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

enthalten in: British journal of cancer | 2022

von de Gregorio, A. | Janni, W. | Friedl, T. | +17

9

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

enthalten in: Cancer medicine | 2021

von Grote, I. | Bartels, S. | Kandt, L. | +20

10

Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Hein, A. | Hartkopf, A. | Emons, J. | +27